

Referências

1. Blank CU(1), Larkin J(2), Arance AM(3), Hauschild A(4), Queirolo P(5), Del Vecchio M(6), Ascierto PA(7), Krajsova I(8), Schachter J(9), Neyns B(10), Garbe C(11), Chiarion Sileni V(12), Mandalà M(13), Gogas H(14), Espinosa E(15), Hossers GAP(16), Miller WH Jr(17), Robson S(18), Makrutzki M(19), Antic V(20), Brown MP(21). Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. *Eur J Cancer*. 2017 Jul;79:176-184. doi: 10.1016/j.ejca.2017.04.007. Epub 2017 May11.
2. Boada A, Carrera C, Segura S, Collgros H, Pasquali P, Bodet D, Puig S, Malveyh J. Cutaneous toxicities of new treatments for melanoma. *Clin Transl Oncol*. 2018 May 24.
3. Chen, F. W., Tseng, D., Reddy, S., Daud, A. I., & Swetter, S. M. (2014). Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy. *JAMA Dermatology*, 150(11), 1209–4.
4. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. *Nat Rev Immunol*. 2013 Apr;13(4):227-42. doi: 10.1038/nri3405. *Nat Rev Immunol*. 2013 Jul;13(7):542
5. Cohen, P. R., Bedikian, A. Y., & Kim, K. B. (2013). Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib. *The Journal of Clinical and Aesthetic Dermatology*, 6(5), 27–37.
6. Davies M, Hennessy B, Mills GB. Point mutations of protein kinases and individualised cancer therapy. *Expert Opin Pharmacother*. 2006;7:2243–2261
7. Harada, K., Kato, Y., Maeda, T., Yoshida, M., Irisawa, R., Nagao, T., & Tsuboi, R. (2016). N-Ras mutation in vemurafenib-associated expanding melanocytic nevus. *The Journal of Dermatology*, 44(5), e101–e102
8. Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. *Oncologist*. 2013;18:314-22
9. Larkin J(1), Del Vecchio M(2), Ascierto PA(3), Krajsova I(4), Schachter J(5), Neyns B(6), Espinosa E(7), Garbe C(8), Sileni VC(9), Gogas H(10), Miller WH Jr(11), Mandalà M(12), Hossers GA(13), Arance A(14), Queirolo P(15), Hauschild A(16), Brown MP(17), Mitchell L(18), Veronese L(18), Blank CU(19) Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. *Lancet Oncol*. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 2
10. Millán-Cayetano, J. F., Fernández-Canedo, I., Blázquez-Sánchez, N., Fúnez-Liévana, R., & de Troya-Martín, M. (2017). BRAFV600E Mutation in Involuting Nevus in a Patient Treated With Vemurafenib. *JAMA Dermatology*, 2016
11. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. *Curr Opin Oncol*. 2011 Mar;23(2):177-82.
12. Speeckaert, R., Van Geel, N., Vermaelen, K. V., Lambert, J., Van Gele, M., Speeckaert, M. M., & Brochez, L. (2010). Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. *Pigment Cell & Melanoma Research*, 24(2), 334–344. <http://doi.org/10.1111/j.1755-148X.2010.00799.x>.
13. Zimmer L(1), Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, Egberts F, Hauschild A, Kashani-Sabet M, Goldinger SM, Dummer R, Long GV, McArthur G, Scherag A, Sucker A, Schadendorf D. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. *J Clin Oncol*. 2012 Jul 1;30(19):2375-83